Lexeo Therapeutics announces research collab with Johnson & Johnson

Lexeo Therapeutics (LXEO) announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy. The collaboration seeks to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV delivery to the heart by investigating cutting-edge routes of administration using Impella heart pump technology. “This collaboration represents an exciting step toward unlocking the full potential of cardiac gene therapy,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “By concentrating delivery to the heart with localized routes of administration leveraging Impella heart pumps, we aim to substantially reduce required AAV doses and improve gene therapy safety while maximizing transgene expression and clinical efficacy. We are thrilled to pair Lexeo’s leadership in cardiac genetic medicine with Impella’s world-class technology to advance a next generation of targeted genetic medicines for cardiovascular disease.”